PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 17028636

[The Norwegian vaccination program].

Hanne Nøkleby·Berit Feiring
View original source ↗Export metadata ↓

Abstract

Development of vaccines has in many ways been the art of the possible, using current knowledge about infections and microbes to devise new products. The aim of every vaccination is to prevent disease, but use of vaccines within vaccination programs is usually targeted not only to protect the individual, but also to changing the epidemiology of the disease. Several new vaccines will become available during the next decade, but the vaccination program will probably not be dramatically changed. Increased knowledge about the immune system might, in a longer time perspective, make it possible to rebuild a vaccination program on a new basis. Immunisations can perhaps be used for targeting the immune system in ways that still give protection against the specific infections, but in addition lead to better health through general protection against diseases, less allergy and less autoimmune diseases than we have today.

Explore related subjects

Bacterial VaccinesHistory, 19th CenturyHistory, 20th CenturyHumansImmunization ProgramsNorwayVaccinationViral VaccinesEnglish AbstractHistorical ArticleJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hanne Nøkleby, Berit Feiring. 2006-10-05. [The Norwegian vaccination program].. https://pubmed.ncbi.nlm.nih.gov/17028636/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison.

Francisella tularensis is a bacterial pathogen that causes the zoonotic disease tularemia and is important to biodefense. Currently, the only vaccine known to confer protection against tularemia is a specific live vaccine strain (designated LVS) derived from a virulent isolate of Francisella tularensis subsp. holarctica. The origin and source of attenuation of this strain are not known. To assist with the design of a defined live vaccine strain, we sought to determine the genetic basis of the attenuation of LVS. This analysis relied primarily on the comparison between the genome of LVS and Francisella tularensis holarctica strain FSC200, which differ by only 0.08% of their nucleotide sequences. Under the assumption that the attenuation was due to a loss of function(s), only coding regions were examined in this comparison. To complement this analysis, the coding regions of two slightly more distantly related Francisella tularensis strains were also compared against the LVS coding regions. Thirty-five genes show unique sequence variations predicted to alter the protein sequence in LVS compared to the other Francisella tularensis strains. Due to these polymorphisms, the functions of 15 of these genes are very likely lost or impaired. Seven of these genes were demonstrated to be under stronger selective constraints, suggesting that they are the most probable to be the source of LVS attenuation and useful for a newly defined vaccine.

Bacterial Vaccines↗
PubMed2006

[Gender differences in response to preventive health care interventions. Do we have to treat girls and boys differently to treat them equally?].

In spite of well-recognised differences in morbidity patterns among boys and girls, differences in their response to common interventions like vaccinations have rarely been considered. Our research in vaccinations and vitamin A supplementation has suggested sex differences in the response to these interventions. If these observations reflect a general pattern, it may be that, in order to be treated equally, boys and girls should be treated differently.

Bacterial Vaccines↗
PubMed2006

Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape.

Francisella tularensis is a Gram-negative bacterium and the causative agent of tularemia. Recent data indicate that F. tularensis replicates inside macrophages, but its fate in other cell types, including human neutrophils, is unclear. We now show that F. tularensis live vaccine strain (LVS), opsonized with normal human serum, was rapidly ingested by neutrophils but was not eliminated. Moreover, evasion of intracellular killing can be explained, in part, by disruption of the respiratory burst. As judged by luminol-enhanced chemiluminescence and nitroblue tetrazolium staining, neutrophils infected with live F. tularensis did not generate reactive oxygen species. Confocal microscopy demonstrated that NADPH oxidase assembly was disrupted, and LVS phagosomes did not acquire gp91/p22(phox) or p47/p67(phox). At the same time, F. tularensis also impaired neutrophil activation by heterologous stimuli such as phorbol esters and opsonized zymosan particles. Later in infection, LVS escaped the phagosome, and live organisms persisted in the neutrophil cytosol for at least 12 h. To our knowledge, our data are the first demonstration of a facultative intracellular pathogen, which disrupts the oxidative burst and escapes the phagosome to evade elimination inside neutrophils, and as such, our data define a novel mechanism of virulence.

Bacterial Vaccines↗